Author

M. M. Patnaik

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Research Focus:differential expression· 2 Assay:whole-exome sequencing· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

M. Binder· 3 shared A. Vedder· 2 shared E. Padron· 2 shared G. Coltro· 2 shared J. Zhang· 2 shared M. E. Balasis· 2 shared M. E. Fernandez-Zapico· 2 shared R. M. Carr· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Binder

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML

C. Letson, M. E. Balasis, H. Newman, M. Binder, A. Vedder, F. Kinose, M. Ball, T. Kruer, A. Quintana, T. L. Lasho, C. M. Finke, L. L. Almada, J. M. Grants, G. Zhang, M. E. Fernandez-Zapico, , E. Padron

This study identifies PIM inhibitors as synergistic with BET inhibitors in myeloid leukemia, showing miR-33a downregulation drives PIM1 upregulation and GM-CSF hypersensitivity as a biomarker for combination therapy.

bioRxiv · Nov 1, 2022Cancer Biology

Genomic and transcriptional profiling stratifies VQ myeloma lines into two clusters with distinct risk signatures and drug responses

E. Flietner, M. Yu, A. Rajagopalan, Y. Zhou, Y. Feng, A. Veltri, T. Lasho, Z. Wen, Y. Sun, M. M. Patnaik, N. S. Callander, F. Asimakopoulos, D. Wang, J. Zhang

bioRxiv · Aug 21, 2022 · PreprintCancer Biology

Indoleamine 2,3-dioxygenase-1 expressing aggregate bone marrow dendritic cell populations are associated with systemic T cell compartment changes in chronic myelomonocytic leukemia

A. Mangaonkar, K. K. Reichard, M. Binder, G. Coltro, T. L. Lasho, R. M. Carr, A. Chiu, V. Negron, M. Hefazi, T. Anagnostou, J. C. Villasboas, W. Gonsalves, N. Gangat, M. Shah, H. B. Alkhateeb, , M. M. Patnaik

This study examines the association between IDO1+ dendritic cell populations in CMML bone marrow and systemic T-cell changes, finding correlations with disease progression and immune suppression.

bioRxiv · May 14, 2020 · PreprintImmunology

RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis

R. M. Carr, D. Vorobyev, T. Lasho, D. L. Marks, E. J. Tolosa, A. Vedder, L. Almada, A. Yurchenko, I. Padioleau, B. Alver, G. Coltro, M. Binder, S. L. Safgren, I. Horn, X. You, , M. M. Patnaik

This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.

bioRxiv · Dec 23, 2019 · PreprintCancer Biology